Nuvation Bio Inc. Common Stock and Additional Paid-In Capital
Nuvation Bio Inc. (NUVB) had Common Stock and Additional Paid-In Capital of $116.99 million as of 2024-03-31, per its 8-K/A filed 2024-06-20.
Discontinued › Notes › Equity
us-gaap:CommonStocksIncludingAdditionalPaidInCapital · last filed 2024-06-20
- 2024-03-31: Common Stocks, Including Additional Paid in Capital $116.99M.
| Period end | Common Stocks, Including Additional Paid in Capital |
|---|---|
| 2024-03-31 | $116.99M 8-K/A · filed 2024-06-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |